The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of S-1 plus oxaliplatin combined with radiation (SOX/RT) for preoperative locally advanced rectal carcinoma (JACCRO CC-04: SHOGUN trial).
Toshiaki Watanabe
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Satoshi Matsusaka
No relevant relationships to disclose
Soichiro Ishihara
No relevant relationships to disclose
Keisaku Kondo
No relevant relationships to disclose
Hisanaga Horie
No relevant relationships to disclose
Keisuke Uehara
No relevant relationships to disclose
Masahiko Oguchi
No relevant relationships to disclose
Keiko Murofushi
No relevant relationships to disclose
Masashi Ueno
No relevant relationships to disclose
Nobuyuki Mizunuma
No relevant relationships to disclose
Daiki Kato
No relevant relationships to disclose
Yojiro Hashiguchi
No relevant relationships to disclose
Taiju Shimbo
No relevant relationships to disclose
Junji Okuda
No relevant relationships to disclose
Masanori Nakazawa
No relevant relationships to disclose
Eiji Sunami
No relevant relationships to disclose
Kazushige Kawai
No relevant relationships to disclose
Hideomi Yamashita
No relevant relationships to disclose
Tohru Okada
No relevant relationships to disclose
Yuichi Ishikawa
No relevant relationships to disclose